

10/519330

09 Rec'd PCT/PTO 23 DEC 2004

PATENT

ATTORNEY DOCKET NO. 50304/056001

Certificate of Mailing


Date of Deposit: December 23, 2004

Label Number: EV 567481991 US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De LaCruz

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter Carmeliet et al. Art Unit: Not yet assigned

Serial No.: Not yet assigned Examiner: Not yet assigned

Filed: December 23, 2004 Customer No.: 21559

Title: PLACENTAL GROWTH FACTOR AS A TARGET FOR THE
TREATMENT OF OSTEOPOROSIS

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a Sequence Listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 1 page.

As required by 37 C.F.R. § 1.821(c), the Sequence Listing appears as a separate part of the application. Each sequence in the application appears separately in the Sequence Listing, and each sequence in the Sequence Listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the Sequence Listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form of the Sequence Listing are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 23 December 2004



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

10/519330**DT09 Rec'd PCT/PTO 23 DEC 2004**

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnologie vzw
K.U.Leuven Research and Development

<120> PLACENTAL GROWTH FACTOR AS A TARGET FOR THE TREATMENT OF OSTEOPOROSIS

<130> PCA-Ost-118A

<160> 1

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> a peptide to which there is antigen specificity

<400> 1

Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu L ys Gly Thr Gln His
1 5 10 15

Ile Met Gln Ala

20

SEQUENCE LISTING

<110> Carmeliet, Peter
Collen, Désiré
Bouillon, Roger
Carmeliet, Gertrudis

<120> PLACENTAL GROWTH FACTOR AS A TARGET FOR
THE TREATMENT OF OSTEOPOROSIS

<130> 50304-056001

<150> PCT/EP2003/050274

<151> 2003-06-27

<150> EP 02077591.2

<151> 2002-06-28

<160> 1

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> a peptide to which there is antigen specificity

<400> 1

Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gln His

1

5

10

15

Ile Met Gln Ala

20